IP Library Granted Patent US 9,409,037
Granted Patent B2
US 9,409,037 · App. 13/006,274 · Granted Aug 9, 2016

Enhanced anti-microbial PDT

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,409,037
App. No.
13/006,274
Granted
Aug 9, 2016
Kind
B2
Abstract

Methods and devices to eliminate, reduce, destroy and/or inhibit undesired body fluid species, such as pathogen microbes and deteriorated or malignant cells in complex environments like blood, serum and other body fluids are provided. In preferred embodiments, an antimicrobial photodynamic therapy (PDT) treatment is given that effectively inactivates, reduces and/or destroys both Gram (−) and Gram (+) bacteria in complex body fluids. Methods to enhance antimicrobial PDT activity include administering a photosensitizer to bacteria-contaminated fluid, after a dwell time guiding bacteria-contaminated fluid with photosensitizer through a channel, emitting radiation preferably in an intermittent manner, and restoring treated body fluids to corresponding body regions. Electromagnetic radiation is preferably delivered intermittently with pulse width based on treatment parameters. Additionally, the method/device diminishes adverse host's inflammatory responses by neutralizing the biological activity of pathogenic microorganism fragments and reducing and/or removing pathogenic microorganism fragments responsible for it.

Claims (18)

1. A method for enhanced photodynamic therapy aiming to reduce, kill or eliminate undesired body fluid species found in diluted or undiluted serum or solutions containing blood or blood compounds from a living organism, comprising the steps of:

a) mixing a photosensitizer with a complex body fluid comprising whole blood;

b) waiting a preselected dwell time to permit association of said photosensitizer and undesired body fluid species of the complex body fluid;

c) passing the complex body fluid associated with the photosensitizer through a filter and separating plasma from the whole blood;

d) guiding said separated plasma through an array of cylindrical channels containing LED-panels at least three times at a flow rate of 10 ml/min;

e) irradiating said separated plasma with an electromagnetic radiation source tuned to an activation wavelength of the selected photosensitizer;

f) processing the irradiated plasma to remove, neutralize or inactivate endotoxins, pathogenic microorganism fragments, dead cells, pathogenic microorganisms, excess or non-activated photosensitizer molecules;

g) combining the processed plasma with the whole blood from which the plasma was separated in step c to form a venous return fluid; and

h) returning said venous return fluid to its corresponding body regions of the living organism.

2. The method according to claim 1 , wherein said photosensitizer is selected from the group consisting of a photosensitizer, a photosensitizer composition and a photosensitizer precursor.

3. The method according to claim 2 , wherein said photosensitizer is Safranin O.

4. The method according to claim 1 , wherein said irradiating step is characterized by application of pulsed electromagnetic radiation.

5. The method according to claim 4 , wherein a pattern of said application of pulsed electromagnetic radiation has a pulse width selected according to contamination degree, bacteria-contaminated fluid flow, photosensitizer dose, electromagnetic radiation power, electromagnetic radiation energy, time and combinations of them.

6. The method according to claim 1 , wherein said undesired body fluid species refers to pathogenic microorganisms, including bacteria and viruses.

7. The method according to claim 6 , wherein said bacteria includes Gram (+) and Gram (−) bacteria.

8. The method according to claim 1 , wherein said undesired body fluid species refers to deteriorated or malignant cells, such as cancer cells.

9. The method according to claim 1 , wherein said method further comprises the step of removing or inactivating excess or non-activated photosensitizer present in the separated plasma or whole blood by adjusting the electromagnetic radiation pattern of delivery, delivering electromagnetic radiation many times, using a photosensitizer-absorber or by any other means.

10. The method according to claim 1 , wherein said photosensitizer is mixed with the complex body fluid inside the living organism or outside of said living organism.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041182/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2013
From: CERAMOPTEC INDUSTRIES, INC.
To: BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 030245/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2011
From: ALBRECHT, VOLKER; WIELAND, GERHARD; GITTER, BURKHARD; NEUBERGER, WOLFGANG
To: CERAMOPTEC INDUSTRIES, INC.
Reel/Frame 025637/0275 →